Ranitidine Blow Sees Indian Firms Take Different Paths

Solara To Reassign Capacities, Strides Considers Relaunch

A double blow to ranitidine medicines - suspension in the EU and a withdrawal request in the US - has caused Indian API and formulation manufacturers to recalibrate their strategies. Amid uncertainty over future prospects for the gastrointestinal drug, Strides is considering a relaunch in the US while Solara is reassigning part of its capacity to manufacture other APIs.

Signpost
What's At The End Of The Road For Indian Ranitidine Manufacturers? • Source: Shutterstock

It may or may not be the end of the road for ranitidine medicines, but Indian companies affected by a suspension of these drugs by the European Medicines Agency (EMA) and a withdrawal request by the US Food and Drugs Administration (FDA) are taking different strategies to cope with continuing blows to the heartburn medicine that was a significant contributor to their revenues.

Taking different actions, active pharmaceutical ingredients (API) manufacturer Solara Active Pharma Sciences Ltd. is reassigning part of its capacity to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip